induction of the mRNA of the LDL receptor (LDL-R) than by other statins. 17 Conversion of cholesterol to bile acids plays an important role in determining whole-body cholesterol homeostasis, 18, 19 and cholesterol 7 -hydroxylase (CYP7A1) is the initial and rate-limiting enzyme in the main bile acid biosynthetic (classic or neutral) pathway. 18, 20 The importance of CYP7A1 in cholesterol homeostasis is highlighted by three findings: (1) increasing hepatic CYP7A1 by bile acid depletion substantially reduces plasma cholesterol concentrations in Watanabe heritable hyperlipidemic (WHHL) rabbits, 21 in which LDL-R does not function, (2) inhibition of apical sodium codependent transporter (SLC10A2; also known as ASBT or ileal bile acid transporter, IBAT) by PR835 increases enzymatic activity and mRNA levels of CYP7A1 and drastically reduces plasma very-low-density lipoprotein (VLDL) and LDL-C in mice lacking both LDL-R and apolipoprotein (apo) E, 22 and (3) overexpression of hepatic CYP7A1 in mice lacking the LDL-R gene markedly decreases plasma concentrations of VLDL cholesterol (VLDL-C) and LDL-C. 23 The reduction in the concentration of LDL in the absence of the LDL-R gene or function by increasing CYP7A1 was caused, in large part, by intrahepatic diversion of cholesterol destined for circulating (VLDL and LDL) lipoproteins in plasma to bile acid synthesis and, therefore, to a decrease in the rate of LDL-C transfer into the plasma space. 23 Pitavastatin has been shown to decrease apo B-100 secretion from HepG2 cells through increased intracellular degradation of newly synthesized protein 24 and to strongly reduce VLDL secretion in WHHL rabbits 25 and guinea pigs. 26 Because of the striking parallel between the effects Circulation Journal Vol.68, November 2004 of pitavastatin and bile acid depletion on cholesterol metabolism in the absence of LDL-R, we hypothesized the existence of a common mechanism involving CYP7A1.
Because of the importance of CYP7A1 in cholesterol homeostasis, the effects of the inhibition of HMG-CoA reductase by old-generation statins on the regulation of bile acid synthesis in humans have been investigated in previous studies, but the results are controversial. [27] [28] [29] [30] [31] [32] Lovastatin had an inhibitory effect on CYP7A1 activity in rat liver; 31, 33 pravastatin had no significant effect on CYP7A1 activity in human subjects; 34 simvastatin decreased CYP7A1 mRNA levels in guinea pigs, 35 but did not affect 7 -hydroxylation rates in human subjects; 36 atorvastatin decreased CYP7A1 mRNA levels in guinea pigs, 35 showed no significant effects on plasma 7 -hydroxy-4-cholesten-3-one, a validated marker of bile acid synthesis, in FH heterozygotes 30 and enhanced the effects of IBAT inhibition by PR835 on CYP7A1 mRNA and LDL-C levels in mice lacking both LDL-R and apo E. 22 However, the superstatin, pitavastatin, has been shown to slightly increase the level of CYP7A1 mRNA in guinea pigs, 35 but there is still no information available regarding its effects on CYP7A1 in humans.
The enzymatic conversion of cholesterol into bile acids is regulated through feedback suppression by bile acids 18, 37 and feedforward induction by cholesterol, 18, 38, 39 mediated by the orphan nuclear receptors, farnesoid X receptor (FXR) and liver X receptor (LXR), respectively. 18, 40 The human CYP7A1 gene lacks the LXR response elements that have been identified in the rat and mice CYP7A1 genes, 18, 39 although there is in vivo 41 and in vitro 42 evidence that cholesterol also regulates CYP7A1 and bile acid synthesis in humans. It is clear that regulation at the level of gene transcription and/or mRNA degradation is the primary determinant of CYP7A1 activity 43 because a positive correlation has been found between CYP7A1 mRNA abundance and CYP7A1 enzymatic activity. 43 The overexpression of peroxisome proliferator-activated receptor (PPAR ), a nuclear receptor that regulates fatty acid metabolism, inhibits the transcription of the CYP7A1 gene in HepG2 cells 44, 45 and the activation of PPAR by fibrates or the PPAR agonist Wy14643 also decreases CYP7A1 activity or mRNA levels in humans and animals. [46] [47] [48] Pitavastatin has been shown to increase apo A-I mRNA levels by increasing PPAR activity in HepG2 cells. 49 Therefore, we examined the effects of pitavastatin on the mRNA levels of apo A-I, PPAR , CYP7A1, and FXR in HepG2 cells, an established model for studies of the regulation of the human CYP7A1 gene at the molecular level. 42, 50 
Methods

Materials
Pitavastatin (NK-104) was kindly provided by Kowa Inc, Fukuoka, Japan; DL-mevalonic acid lactone was purchased from Sigma (St Louis, MO, USA); human hepatoma HepG2 cells were obtained from RIKEN Cell Bank (RCB 0459, Japan); bovine serum albumin (BSA: fatty acid-free grade) was purchased from TRACE Biosciences NZ Ltd (New Zealand); and Dulbecco's Modified Eagle Medium (DMEM) and other culture supplements were purchased from Gibco BRL (Invitrogen, Carlsbad, CA, USA).
Cell Culture and RNA Preparation
Human hepatoma HepG2 cells were maintained in DMEM containing 100 units/ml penicillin and 100 g/ml streptomycin, and supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 5% CO2. At approximately 60-70% confluence, the medium was replaced by a serum-free medium containing 0.5% BSA (fatty acid-free) for 18 h before treatment with NK-104 to avoid interference by serum components. Pitavastatin was dissolved in water. A stock solution of mevalonate salt (0.1 mol/L) was made by incubating DL-mevalonic acid lactone with 0.1 N NaOH at 50°C for 2 h, 51 and stored at -30°C until use. Cells were subsequently incubated with the indicated compounds for the indicated period of time. At the end of the treatment period, total RNA was extracted using RNAzol B Reagents (TEL-TEST, Inc, Friendswood, USA) according to the manufacturer's instructions.
Quantification of mRNA Levels by Reverse Transcription (RT) and Real-Time Polymerase Chain Reaction (PCR)
cDNA was reverse-transcribed from the total RNA using a TaqMan Reverse Transcription Reagent Kit (PE Applied Biosystems, Roche Molecular Systems, Inc, NJ, USA). Oligo d(T) 16 was used for the primers. The RT reaction was performed in a reaction volume of 30 l at 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min (GeneAmp PCR System 9600, Perkin Elmer, USA), as described previously. 52 Oligonucleotide primers for PCR amplification were designed from the GenBank cDNA sequences of the human apo A-I (accession no. XM006435), PPAR (accession no. NM005036), CYP7A1 (accession no. NM000780), and FXR (accession no. NM005123) genes using Primer Express (Version 1.0, PE Applied Biosystems). Primers for a housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were purchased from PE Biosystems (Warrington, UK). Real-time PCR of apo A-I, PPAR , CYP7A1, FXR, and GAPDH was performed using SYBR Green PCR Core Reagents (PE Biosystems) in the Gene Amp 5700 Sequence Detection System (PE Biosystems, Tokyo, Japan) with the primers described in Table 1 . The amplification reactions were performed in a final volume of 50 l, with thermal cycling conditions of 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C, 15 s at 58°C, and 1 min at 72°C, as described previously. 52 Samples were assayed in triplicate. The relative standard curve method was used to quantitate apo A-I, PPAR , CYP7A1, FXR, and GAPDH mRNA levels. 53 
Statistical Analysis
All of the statistical analyses were performed using the SAS (Statistical Analysis System) Software Package (Version 8.2, SAS Institute Inc, Cary, NC, USA) in Fukuoka University. Data are presented as the mean ± standard deviation. Significant effects of pitavastatin on gene expression were examined by an analysis of variance (ANOVA). The significance level was considered to be 5% unless indicated otherwise.
Results
Dose-Dependent Effects of Pitavastatin on mRNA Levels of Apo A-I, PPAR , CYP7A1, and FXR in HepG2 Cells
Human HepG2 cells were treated with different concentrations of pitavastatin (0.1, 1, 5, 10 mol/L) for 24 h, and the mRNA levels of apo A-I, PPAR , CYP7A1, and FXR were quantified. Treatment with pitavastatin increased the mRNA levels of apo A-I, PPAR , CYP7A1, and FXR in a dose-dependent manner, as assessed by an ANOVA (Fig 1) . As shown in Fig 1, pitavastatin at 0 .1 mol/L was already effective at increasing the apo A-I, PPAR , and CYP7A1 mRNA levels. Pitavastatin at 10 mol/L had the greatest effect on apo A-I, PPAR , CYP7A1, and FXR mRNA levels. The mRNA levels of apo A-I, PPAR , CYP7A1, and FXR similarly increased with increasing doses of pitavastatin, which suggests that pitavastatin not only increases reverse cholesterol transport by increasing apo A-I, but also may increase the conversion of cholesterol to bile acid by increasing CYP7A1.
Effects of Mevalonate on the Induction of Apo A-I, PPAR , CYP7A1, and FXR mRNA Levels by Pitavastatin in HepG2 Cells
To demonstrate that the increase in the apo A-I, PPAR , CYP7A1, and FXR mRNA levels with pitavastatin treatment is caused by the inhibition of HMG-CoA reductase by pitavastatin, we examined the effects of mevalonate (4 mmol/L), the product of HMG-CoA reductase, on the induction of apo A-I, PPAR , CYP7A1, and FXR mRNA levels by pitavastatin (5 mol/L). As shown in Fig 2, the apo A-I, PPAR , and CYP7A1 mRNA levels in cells treated with pitavastatin at 5 mol/L were higher than those in untreated cells. Simultaneous incubation of pitavastatin with mevalonate completely reversed the effects of pitavastatin on the apo A-I, PPAR , CYP7A1, and FXR mRNA levels (Fig 2) . This result indicates that the inductive effects of pitavastatin on apo A-I, PPAR , CYP7A1, and FXR mRNA were caused by its inhibition of HMG-CoA reductase.
Discussion
The present study examined the effects of pitavastatin on mRNA levels of CYP7A1 in HepG2 cells and a surprising result was that pitavastatin dose-dependently increased CYP7A1 mRNA levels and mevalonate reversed the inductive effects of pitavastatin on CYP7A1 mRNA. This suggests that pitavastatin increases the conversion of cellular cholesterol to bile acids, which may contribute to its potent . mRNA levels were quantified as described in the text and expressed relative to the untreated control set at 1 (means ± SD, *p<0.05 vs untreated control cells, by an ANOVA). RAU, relative arbitrary units. Experiments were performed in triplicate, and three independent experiments were performed. cholesterol-lowering effects. Our finding supports that of Aoki et al who reported that pitavastatin slightly increases CYP7A1 mRNA levels in guinea pigs 35 and is in agreement with that of Galman et al, 22 who reported that atorvastatin enhances the effect of IBAT inhibition on CYP7A1 mRNA levels in mice lacking both LDL-R and apo E. However, our finding does not agree with those of other authors who have reported no significant effects of lovastatin, 54 pravastatin, 34 simvastatin 35, 36 or atorvastatin 30, 35 on CYP7A1.
The factors that contribute to the differences in the effects of the different statins on CYP7A1 are not fully understood. First, pitavastatin differs from simvastatin 55 and pravastatin 56 in both its potency at inhibiting sterol synthesis and the duration of this effect. 55 Suzuki et al showed in the guinea pig that pitavastatin at 1 mg/kg decreased hepatic sterol synthesis at 3 h to a similar extent as simvastatin at 15 mg/kg and that the effect of pitavastatin lasted up to 9 h whereas that of simvastatin was attenuated after 6 h and disappeared after 9 h. 55 Indeed, Pandak et al showed that CYP7A1 activity in rat was maximally decreased by lovastatin between 3 and 6 h and recovered after 27 h, and that the reduction of bile acid synthesis was closely correlated with the changes in the activity of CYP7A1. 33 However, there is no firm evidence that the half-lives of these drugs are related to their effects on CYP7A1. In fact, Aoki et al reported that both the longlasting statins atorvastatin and simvastatin decreased CYP7A1 mRNA levels in guinea pigs. 35 Second, pitavastatin is more efficient at increasing the LDL-R in HepG2 cells than other statins, including pravastatin and atorvastatin. 17 Mazzella et al, who showed that simvastatin had no significant effect on bile acid synthesis in patients with nonfamilial hypercholesterolemia, suggested that the inhibition of cholesterol synthesis is not sufficient to reduce bile acid synthesis that may largely depend on the available preformed intrahepatic cholesterol. 57 In addition, the inhibitory effects of lovastatin on CYP7A1 activity in rats were abolished by cholesterol in the diet. 31 However, it is not likely that the effects of statins on CYP7A1 depend on their effects on the LDL-R, considering that atorvastatin enhanced the effects of IBAT inhibition on CYP7A1 mRNA levels in mice lacking both LDL-R and apo E 22 and decreased the rate of bile acid synthesis when that bile acid was upregulated by either partial ileal bypass or bile acid sequestrants in patients with heterogeneous FH. 30 Third, pitavastatin differs from simvastatin in its effects on VLDL secretion. Pitavastatin at 3 mg/kg decreased VLDL-triglyceride and VLDL-apo B secretion in the guinea pig, whereas simvastatin at 30 mg/kg had no significant effect. 55 Although our finding supports the hypothesis that the suppressive effect of pitavastatin on VLDL secretion may be attributable to an increased conversion of cholesterol to bile acids, it is not clear whether or not the results obtained in vitro may be applied to the pathophysiology in human subjects, in whom bile acids are continuously reabsorbed in the intestine.
Feedback regulation of CYP7A1 by bile acids is known to be mediated by FXR and activation of FXR suppresses the CYP7A1 gene. 18 However, we observed a simultaneous increase in mRNA levels of FXR and CYP7A1, and the reason for this result is unclear. It is possible that some other factor(s) that counterbalances the suppressive effects of FXR may exist in the mevalonate/cholesterol pathway. Further investigations are needed to clarify this point.
It has been reported that overexpression of PPAR and the activation of PPAR by fibrates or Wy14643 decrease CYP7A1 mRNA levels and enzyme activity. [44] [45] [46] [47] [48] Our finding that pitavastatin treatment dose-dependently increased apo A-I mRNA levels in HepG2 cells agrees with that of Martin et al. 49 The in vitro data agree with the finding that pitavastatin treatment increases plasma apo A-I levels in patients with primary hypercholesterolemia. 6 Our finding that pitavastatin also increases the PPAR mRNA levels agrees with that of Martin et al who found that pitavastatin enhances PPAR activity in rabbit kidney RK13 cells. 49 Therefore, PPAR did not appear to have an inhibitory effect on the CYP7A1 gene under our experimental conditions, which supports the finding by other authors that PPAR is unlikely to be a major influence on CYP7A1 Fig 2. Effects of mevalonate on the induction of apo A-I, PPAR , CYP7A1, and FXR mRNA levels by pitavastatin in HepG2 cells. HepG2 cells were pretreated for 2 h with 4 mmol/L of mevalonate or appropriate solvent in serum-free medium containing 0.5% BSA (fatty acid-free), and then coincubated with mevalonate and pitavastatin (5 mol/L) for 24 h. mRNA levels were quantified as described in the text and expressed as means ± SD relative to the untreated control set at 1. *p<0.05 vs untreated control cells; † p<0.05 vs pitavastatin-treated cells. RAU, relative arbitrary units. Experiments were performed in triplicate, and three independent experiments were performed. activity under normal physiological conditions. 45 In conclusion, the present study shows that pitavastatin increases the CYP7A1 mRNA levels in HepG2 cells, which suggests a novel mechanism for the potent LDL-C-lowering effects of pitavastatin (ie, increased conversion of cellular cholesterol into bile acids). However, the effects of pitavastatin on bile acid synthesis in human subjects warrant further investigation.
A low levels of high-density lipoprotein cholesterol (HDL-C) is a known risk-factor for CHD 1 and the balance between HDL and LDL is important in predicting the risk of CHD. Therefore, approaches to raising high-dinsity lipoprotein (HDL) have attracted much attention. Although the ability of statins to raise HDL is limited, the inhibition of cholesterol estertransfer protein (CETP) by small molecules, including JTT-705 and torcetrapib, has been shown to effectively increase HDL levels in humans with normal and low HDL-C levels. [58] [59] [60] Therefore, pitavastatin could be a promising basal drug for complementary CETP inhibitors. In addition, the combination of a statin and a bile acid sequestrant, which indirectly depletes the intrahepatic C pool, or the combination of a statin and ezetimibe, which inhibits the intestinal absorption of cholesterol, 61 is a potent therapy for achieving target LDL levels in hypercholesterolemia. Therefore, our finding would be clinically important if confirmed in human subjects because a greater synergistic effect of bile acid sequestering resin or ezetimibe on LDL-C levels could be expected in subjects treated with pitavastatin, compared to those taking other statins.
